StreetInsider.com News Articles

Glimpse Group shifts to pureplay Physical AI focus

Thu, 14 May 2026 17:19:06 -0400

The Glimpse Group (NASDAQ: GGRP) announced a strategic transformation to become a pureplay Physical AI company through its subsidiary Brightline Interactive, while reporting financial results for the third quarter ended March 31, 2026.

The company will focus exclusively on Brightline Interactive, which provides Physical AI infrastructure software through its SpatialCore platform. The platform enables AI systems to perceive, decide and act in the real world by creating standardized connections between disparate systems. Brightline has secured contracts with U.S. Department of War entities and Cooperative Research and Development Agreements with the Navy and Army.

As part of the strategic shift, The Glimpse Group

Glimpse Group shifts to pureplay Physical AI focus

Thu, 14 May 2026 17:19:06 -0400

As part of the strategic shift, The Glimpse Group

Glimpse Group shifts to pureplay Physical AI focus

Thu, 14 May 2026 17:19:06 -0400

As part of the strategic shift, The Glimpse Group

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").

Strategic Shift of Glimpse to Brightline Interactive,

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").
Strategic Shift of Glimpse to Brightline Interactive,

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").
Strategic Shift of Glimpse to Brightline Interactive,

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").
Strategic Shift of Glimpse to Brightline Interactive,

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").
Strategic Shift of Glimpse to Brightline Interactive,

The Glimpse Group Becomes A Pureplay Physical AI Company and Announces Q3 Fiscal Year 2026 Financial Results

Thu, 14 May 2026 16:02:00 -0400

The Strategic Shift Includes: Pureplay Physical AI Focus; Direct Equity Investment by Its Two Largest Shareholders, Incoming Board & Execs; Incoming Tier 1 Board; and Executive Changes

NEW YORK, NY / ACCESS Newswire / May 14, 2026 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:GGRP), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, announced a fundamental strategic update and financial results for its third quarter fiscal year 2026, ended March 31, 2026 ("Q3 FY '26").
Strategic Shift of Glimpse to Brightline Interactive,

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Wed, 26 Mar 2025 08:00:00 -0400

Issues Open Letter to Atea’s Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers
Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

HOUSTON--(BUSINESS WIRE)-- Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 5.4% of the outstanding stock of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) (“Atea” or the “Company”), today announced that they have nominated three highly qualified director candidates – Howard